GRI BIO, INC.
Income Statement
| Line Item | FY2021 | FY2020 |
|---|---|---|
| Revenue | $0 | $100.0K |
| Cost of Revenue | — | — |
| Gross Profit | — | — |
| Gross Margin | — | — |
| Operating Expenses | ||
| Research & Development | $5.2M | $3.7M |
| SG&A Expense | $4.1M | $1.2M |
| Operating Income | $-9.3M | $-4.8M |
| Operating Margin | — | -4,788.0% |
| Interest Expense | — | — |
| Pretax Income | — | — |
| Income Tax Expense | — | — |
| Net Income | $-9.3M | $-4.8M |
| Net Margin | — | -4,822.0% |
| EPS (Basic) | $-0.02 | $-0.02 |
| EPS (Diluted) | $-0.02 | $-0.02 |
| Shares Outstanding (Basic) | 392.5M | 270.4M |
| Shares Outstanding (Diluted) | 392.5M | 270.4M |
| Dividends Per Share | — | — |